¡Ya estamos en ! Descubre más
ATHX

Athersys, Inc. Common Stock

Excluida de cotización

ATHX dejó de cotizar en bolsa el 17 de octubre de 2023.

 

Acerca de: Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Empleados: 24

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 0%
Neutral 0%
Negativo 0%

No hemos recibido artículos de noticias recientes sobre ATHX.

Gráficos de precios implementados con Lightweight Charts™